All News

KOL Views: ASCLEPIOS confirms ofatumumab is for real but how well can it compete with Ocrevus?

Ref: KOL Views Desk

Tags: KOL Views Genmab Novartis Roche Multiple Sclerosis FDA Marketing & Sales Medical Affairs Ocrevus ofatumumab

ViewPoints: Damage from BG00011 setback may be limited to Biogen

Ref: ViewPoints Desk

Tags: ViewPoints AbbVie Biogen Morphic Therapeutic Pliant Therapeutics FDA Clinical Research (R&D)BG00011 MORF-720 PLN-74809

VALBIOTIS Presents Positive Results From a Study on TOTUM-63, Active Substance of VALEDIA, Conducted by the CarMeN Laboratory in Lyon, at the Annual Meeting of the European Association for the Study of Diabetes (EASD)

Ref: Business Wire

Tags: Press Release VALBIOTIS Diabetes Clinical Research (R&D) Medical Affairs EASD VALEDIA

Optinose Announces Departure of Chief Commercial Officer

Ref: GlobeNewswire

Tags: People News OptiNose Corporate Affairs

MHRA and the Bill & Melinda Gates Foundation to look at the safer, effective use of medicines during pregnancy

Ref: GOV.UK

Tags: Press Release United Kingdom Pregnancy MHRA Corporate Affairs

Long-term hormone therapy increases mortality risk for men with low PSA levels after prostate surgery

Ref: ASTRO

Tags: Press Release Prostate Cancer Clinical Research (R&D) Medical Affairs ASTRO bicalutamide

Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Children’s Oncology Group Meeting

Ref: Business Wire

Tags: Press Release Oncternal Therapeutics Clinical Research (R&D) Medical Affairs TK216

ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2019

Ref: GlobeNewswire

Tags: Press Release ERYtech Pharma Corporate Affairs

iBio’s Collaboration with South Africa’s AzarGen Biotechnologies Advances to Next Stage

Ref: GlobeNewswire

Tags: Press Release iBio Inc AzarGen Corporate Affairs rituximab

Neurocrine Biosciences to Present Data on INGREZZA (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders

Ref: PR Newswire

Tags: Press Release Neurocrine Voyager Therapeutics Parkinson's Clinical Research (R&D) Medical Affairs International Congress of Parkinson's Disease and Movement Disorders Ingrezza VY-AADC opicapone